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ed March 19, 2013.his study sought to determine whether post-operative neurocognitive dysfunction (POCD) occurs after ablation for
atrial ﬁbrillation (AF).Background Ablation for AF is a highly effective strategy; however, the risk of transient ischemic attack and stroke is
approximately 0.5% to 1%. In addition, magnetic resonance imaging studies report a 7% to 14% prevalence of silent
cerebral infarction. Whether cerebral ischemia results in POCD after ablation for AF is not well established.Methods The study included 150 patients; 60 patients undergoing ablation for paroxysmal atrial ﬁbrillation (PAF), 30 patients
undergoing ablation for persistent atrial ﬁbrillation (PeAF), and 30 patients undergoing ablation for supraventricular
tachycardia (SVT) were compared with a matched nonoperative control group of patients with AF awaiting radiofrequency
ablation (n¼ 30). Eight neuropsychological tests were administered at baseline and at 2 days and 90 days post-operatively.
The testswereadministeredat the same timepoints to thenonoperative control group. The reliable change indexwasused to
calculate POCD.Results The prevalences of POCD at day 2 post-procedure were 28% in patients with PAF, 27% in patients with PeAF, 13% in
patients with SVT, and 0% in control patients with AF (p ¼ 0.007). At day 90, the prevalences of POCD were 13% in
patients with PAF, 20% in patients with PeAF, 3% in patients with SVT, and 0% in control patients with AF (p ¼ 0.03).
When analyzing the 3 procedural groups together, 29 of 120 patients (24%) manifested POCD at day 2 and 15 of
120 patients (13%) at day 90 post-procedure (p ¼ 0.029). On univariate analysis, increasing left atrial access time
was associated with POCD at day 2 (p ¼ 0.04) and day 90 (p ¼ 0.03).Conclusions Ablation for AF is associated with a 13% to 20% prevalence of POCD in patients with AF at long-term follow-up.
These results were seen in a patient population with predominant CHADS2 (Congestive heart failure, Hypertension,
Age 75 years, Diabetes mellitus, previous Stroke/transient ischemic attack) scores of 0 to 1, representing the
majority of patients undergoing ablation for AF. The long-term implications of these subtle changes require further
study. (J Am Coll Cardiol 2013;62:531–9) ª 2013 by the American College of Cardiology FoundationAblation for atrial ﬁbrillation (AF) is a highly effective strategy
for the management of this common arrhythmia. However,
the procedure has a risk of major complications, including
a 0.5% to 1% risk of transient ischemic attack or stroke (1).
Prolonged placement of left atrial catheters and atrial, The Royal Melbourne Hospital, Melbourne,
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2012; revised manuscript received March 12,endocardial damage caused by ablation may trigger thrombus
formation despite use of anticoagulation. Recent magnetic
resonance imaging (MRI) studies have demonstrated the
development of new cerebral lesions after irrigated AF abla-
tion in 7% to 14% of apparently asymptomatic patients (2,3).
Whether subtle neurocognitive dysfunction may occur after
AF ablation procedures has not been well established.
See page 540
We evaluated the prevalence of post-operative cognitive
dysfunction (POCD) in patients after radiofrequency ablation
(RFA) for AF and compared this with a nonprocedural
control population of age-matched patients with AF. We
also studied a group of matched patients with supraventricular
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532tachycardia (SVT) undergoing
ablation as a comparison group.
Methods
Patient selection. The study
included a total of 150 patients
in 4 groups: 1) 60 patients with
paroxysmal AF (PAF) under-
going RFA for drug-refractory
AF; 2) 30 patients with persis-
tent AF (PeAF) undergoing RFA
for drug-refractory AF; 3) 30
patients with SVT undergoing
RFA; and 4) 30 patients with AF
awaiting RFA for symptom-
atic drug-refractory AF (control
group). These patients were
studied during the waiting period
before scheduled ablation. They
were of similar age and met the
inclusion and exclusion criteria
described in the following text.
Consecutive patients presenting
for RFA of AF were approached
for inclusion into the study.
Patients with a history suggestive
of, or who had, documented SVT
and who were of a similar age
group (age 40 to70 years) were alsorecruited. This group was included as an age-matched pop-
ulation of patients undergoing an ablation procedure to control
the effect of general anesthesia on outcomes. Patients were not
speciﬁcally selected based on the presumed location of tachy-
cardia (i.e., left or right sided).Theprotocolwas approvedby the
Melbourne Health Research and Ethics Committee, and
written informed consent was obtained from all patients.
Exclusion criteria included pre-existing neurological or clini-
cally evident neurovascular disease, signiﬁcant pre-morbid
depression and/or anxiety, anticipated difﬁculty with neuro-
cognitive assessment (e.g., deafness, language difﬁculties), and
geographic remoteness.
Ablation procedures. For patients with PAF, the ablation
strategy consisted of wide encirclement of the pulmonary
vein antra without additional adjunctive ablation (4,5). The
endpoint was demonstration of pulmonary vein entrance and
exit block. Patients with PeAF had adjunctive ablation at the
discretion of the treating electrophysiologist.
In patients receiving anticoagulation therapy before
pulmonary vein antral isolation, warfarin was stopped 5 days
before the procedure and treatment with full-dose
low-molecular-weight heparin was commenced. Trans-
esophageal echocardiography was performed in all patients
immediately before the procedure to rule out atrial or atrial
appendage thrombus. A decapolar catheter was positioned in
the coronary sinus and a quadripolar catheter in the Hisbundle position. Two 8.5-F-long sheaths (SL1, St. Jude
Medical, Minneapolis, Minnesota) were introduced into the
left atrium with trans-septal puncture performed under
ﬂuoroscopic and transesophageal echocardiography guid-
ance. A Lasso circular mapping catheter (Biosense Webster,
Foster City, California) or a Reﬂexion spiral catheter (St.
Jude Medical) was introduced through the SL1 sheath into
the left atrium for electrical mapping of the pulmonary veins.
An irrigated ablation catheter (4 mm, D curve, Navistar
Thermocool, BiosenseWebster) was introduced through the
SL1 sheath into the left atrium for ablation (maximum
power: 30 to 35 W). Patients were treated with intravenous
heparin to maintain an activated clotting time (ACT) of 300
to 350 s throughout the procedure. For each patient, anACT
was recorded that represented the mean of all ACTs ob-
tained throughout the procedure.
After ablation, treatment with warfarin was initiated and
enoxaparin was administered at a full dose (1 mg/kg twice
daily) starting 6 h after the procedure. Enoxaparin was
continued until a therapeutic international normalized ratio
(2.0 to 3.0)was attained.Warfarinwas administered for at least
90 days or indeﬁnitely in patients with a CHADS2 (Con-
gestive heart failure, Hypertension, Age 75 years, Diabetes
mellitus, previous Stroke/transient ischemic attack) score 2
(1 point each for congestive heart failure, hypertension,
age 75 years, and diabetes mellitus and 2 points for prior
stroke or thromboembolism). Antiarrhythmic therapy was
continued unchanged for 90 days after the procedure during
the study period. No new antiarrhythmic therapy was initiated
in the post-operative period, and drug therapy remained
constant for the duration of the protocol.
Patients with SVT underwent RFA targeted at the speciﬁc
underlying arrhythmia. In patientswith SVTand an arrhythmia
focus originating from the left atrium requiring trans-septal
access, a single trans-septal puncture was performed, followed
by a bolus of 5,000 U heparin. Thereafter, patients were treated
with intravenous heparin to maintain an ACT of 200 to 250 s
throughout the procedure. Patients with a right-sided SVT
mechanismwere treatedwitha baseline of 2,000Uheparinonly.
Anesthesia. All patients with AF and SVT underwent
RFA while under general anesthesia. Patients were given
induction anesthesia with a combination of propofol, mid-
azolam, and fentanyl. General anesthesia was maintained
throughout the procedure using volatile anesthetic agents
(sevoﬂurane or desﬂurane). Routine measures of oxygenation
and temperature monitoring were documented. Bispectral
Index monitors (BIS, Covidien, Boulder, Colorado) were
used to estimate the depth of anesthesia throughout the
procedure. Arterial blood gas measurements were taken at
random intervals throughout the procedure to measure
intraprocedural factors such as pH, glucose level, and lactate
level that may potentially modify assessments of POCD.
POCD and neuropsychological testing. Neuropsycho-
logical testing comprised 8 tests, based on the Canadian
Study of Health and Aging, administered to all patients by
a trained interviewer (6–10). The results are given as the
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533number of correct answers or the time taken to complete the
test. Testing was administered at 3 time points:
1. Baseline tests were administered within 7 days before
the procedure.
2. Post-procedure tests were administered 24 to 48 h
post-procedure.
3. Late post-procedure tests were administered 90 days
post-procedure.
The individual tests consisted of 8 auditory and written tests,
described in Table 1 (8). These tests included the following:
1. The Consortium to Establish a Registry for Alz-
heimer’s Disease (CERAD) Auditory Verbal Learning
Test (Immediate and Delayed)
2. Trail Making Task Part A
3. Trail Making Task Part B
4. Digit Symbol Substitution Test
5. Controlled Oral Word Association Test
6. CERAD Semantic Fluency Test
7. Grooved Pegboard Test (Dominant Hand)
8. Grooved Pegboard Test (Nondominant Hand)
Absolute test scores were reversed for timed tasks (Trail
Making Task Part A and B, Grooved Pegboard Test
Dominant and Nondominant Hands), so a decrease in test
score reﬂected cognitive decline for all tests (8–10).Table 1 Description of Neuropsychological Tests*
Test Description
CERAD Auditory Verbal
Learning Test-
Immediate
Patients are read a list of 10 words and are asked to reca
maximum number of correct words recalled is documen
2 times; however, the word order is changed each time.
are taken as the scores for this test.
CERAD Auditory Verbal
Learning Test-Delayed
After a 15-min delay after completion of the CERAD Auditor
patients are asked to recall as many of the 10 words as p
or re-reading of the list. The maximum number of correct w
score.
Trail Making Task Part A Consists of 25 circles distributed over a sheet of paper num
instructed to draw lines to connect the numbers in ascen
The time taken to complete the task is taken as the sco
Trail Making Task Part B Consists of 25 circles distributed over a sheet of paper; the
(1–13) and letters (A–L). The patient is instructed to draw
ascending pattern but with the added task of alternating
(i.e., 1-A-2-B-3-C, and so on). The time taken to complete
Digit Symbol Substitution
Test
Requires patients to reproduce on paper, within 90 s, as m
within blank boxes beneath randomly generated digits, a
pairing digits with symbols. The number of correct symbo
the score.
Controlled Oral Word
Association Test
Patients are instructed to say as many words as possible s
60 seconds. F, A, and S are tested.
CERAD Semantic Fluency
Test
Patients are instructed to generate a list of as many words
category (animals) within 60 seconds. The number of co
Grooved Pegboard Test
(Dominant Hand)
Requires patients to insert 25 keyed pegs into a specially
positioned slots. Pegs must be rotated to match the hole
duration taken to complete the task in seconds is taken
Grooved Pegboard Test
(Nondominant Hand)
Requires patients to insert 25 keyed pegs into a specially
positioned slots. Pegs must be rotated to match the hole
duration taken to complete the task in seconds is taken
*Adapted from Silbert et al. (8).
CERAD ¼ The Consortium to Establish a Registry for Alzheimer’s Disease.In addition to the neuropsychological tests, patients were
also administered the following tests:
1. The Mini-Mental State Examination was adminis-
tered to exclude pre-existing cognitive impairment at
baseline.
2. The National Adult Reading Test was administered
to estimate baseline intelligence quotient (IQ).
3. Visual analog scales were administered to assess the
presence of mood disorder and fatigue levels that may
affect the diagnosis of POCD. Patients were asked to
mark a line standardized to 10 cm in length to esti-
mate their current levels of anxiety, depression, and
fatigue (8).
Test scores were analyzed to identify POCD using the
reliable change index (RCI). The RCI rule was applied as
described by Rasmussen et al. (10,11) and was calculated by
subtracting the preoperative score (X1) from the post-
operative score (X2), giving Dx for each individual patient for
each neuropsychological test. The RCI was similarly calcu-
lated for the control group, and the mean expected change
for the controls, Dxc, was then subtracted from the patient’s
score, thereby eliminating any learning and practice effect.
This score was then divided by the SD for the change in test
results of the control group, SD(Dxc), controlling for the
expected variability. These scores were then used to createCognitive Domain
ll as many words as possible. The
ted. This is repeated a further
The results of each individual trial
Memory
y Verbal Learning Test-Immediate,
ossible without further prompting
ords remembered is taken as the
Memory
bered 1–25. The patient is
ding order as quickly as possible.
re.
Executive functioning
circles include both numbers
lines to connect the circles in an
between the numbers and letters
the task is taken as the score.
Executive functioning
any coded symbols as possible
ccording to a coding scheme for
ls reproduced in 90 s is taken as
Memory and processing function
tarting with a given letter within Verbal ﬂuency test, measuring frontal and
temporal lobe function
as possible from a predeﬁned
rrect answers is taken.
Verbal ﬂuency test of semantic memory,
measuring temporal and frontal lobe
function
designed pegboard with randomly
before they can be inserted. The
.
Requires complex visual-motor coordination
and evaluates lateralized injury
designed pegboard with randomly
before they can be inserted. The
.
Requires complex visual-motor coordination
and evaluates lateralized injury
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534a combined test score (SZcombined) using the sum of z-scores
for each test (SZa,b,c,d,etc.) divided by the SD of this
summation in the control group (SD[SZcontrol]). POCD
was deﬁned in an individual when the RCI score was less
than 1.96 on 2 tests and/or the combined z-score was
less than 1.96. This classiﬁes POCD on the basis of
a signiﬁcant failure on 2 tests or a more generalized subtle
decline across the 8 neuropsychological tests (10,11).
This evaluation identiﬁes any change in performance over
time compared with baseline performance. As described in
the preceding text, POCD was considered present with
either a severe deterioration in a few tests or a less severe
deterioration in many tests relative to baseline functioning.
The presence or absence of deﬁcits in control patients with
AF over time (day 2 and day 90) was also assessed to verify
the performance of the control population.
Statistical analysis. Group comparisons were made using
unpaired Student t tests or one-way analysis of variance for
continuous variables, the Kruskal-Wallis test for ranked
data, and chi-square test for dichotomous variables. The type
I error rate was controlled using the Holm-Bonferroni step-
down procedure for multiple comparisons (12). Associations
were determined using univariable analysis. A probability
value of <0.05 indicated statistical signiﬁcance.Results
Baseline characteristics. The baseline and clinical charac-
teristics of the patients with PAF, patients with PeAF,
patients with SVT, and the control population are shown in
Table 2. The mean age was similar across the 4 groups.
There was a higher proportion of men with AF (81%)Table 2 Baseline and Clinical Characteristics
Paroxysmal Atrial
Fibrillation
(n ¼ 60)
Persist
Fibri
(n ¼
Age (yrs) 57  9 53
Male 45 (75) 28
Duration of symptoms (months) 84  72 81
Left ventricular ejection fraction (%) 59  8 55
Hypertension 31 (52) 10
Diabetes mellitus 5 (8) 1
Coronary artery disease 6 (10) 1
Previous transient ischemic attack 2 (3) 1
Hypercholesterolemia 13 (22) 8
Smoker/ex-smoker 13 (22) 4
CHADS2 score 0.75  0.8 0.70
Angiotensin-converting enzyme inhibitor/
angiotensin II receptor blocker
22 (37) 6
Calcium channel blocker 13 (22) 6
Beta-blocker 10 (17) 8
Antiarrhythmic drug (including sotalol) 43 (72) 13
Warfarin 22 (37) 22
Aspirin 32 (53) 5
Values are mean  SD or n (%).
CHADS2 ¼ Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, previous Strokecompared with SVT (43%). Other baseline characteristics,
including CHADS2 risk factors, were comparable between
the groups. Baseline medications are also shown in Table 2.
A higher proportion of patients with PAF were treated with
aspirin and a higher proportion of patients with PeAF were
treated with warfarin before the ablation procedure. Use of
antiarrhythmic drugs and angiotensin-converting enzyme
inhibitors/angiotensin II receptor blockers was higher in
patients with PAF. The proportions of patients treated with
beta-blockers were not signiﬁcantly different between the 4
groups.
Procedural characteristics. Successful pulmonary vein
isolation was achieved in 59 of 60 patients (98%) with PAF
and 29 of 30 patients with PeAF (97%) (p ¼ 1.0). Ten of 30
patients (33%)with PeAFunderwent adjuvant linear ablation,
including 2 of 10 patients who also underwent adjuvant
ablation of complex fractionated electrograms. Of the patients
with SVT, atrioventricular node re-entrant tachycardia was
present in 14 patients, atrioventricular re-entrant tachycardia
in 7 patients, and atrial tachycardia in 5 patients; in addition,
multiple tachycardia mechanisms were present in 4 patients
(2 patients with atrioventricular node re-entrant tachycardia
and atrial tachycardia, 1 patient with atrioventricular re-entrant
tachycardia and atrial tachycardia, and 1 patient with multiple
atrioventricular re-entrant tachycardia pathways). Of these
patients, 7 required trans-septal access for ablation of left-
sided tachycardia and the remaining 23 required right-sided
access only.
A comparison of procedural parameters is shown in
Table 3. There was no difference between patients with
PAF, PeAF, and SVT when comparing depth of anesthesia
(as measured by Bispectral Index score), mean systolic bloodent Atrial
llation
30)
Supraventricular
Tachycardia
(n ¼ 30)
Control
(n ¼ 30) p Value
 10 56  11 53  9 NS
(93) 13 (43) 23 (77) 0.0002
 75 92  180 78  62 NS
 8 59  5 59  5 NS
(33) 8 (27) 10 (33) NS
(3) 3 (10) 1 (3) NS
(3) 2 (7) 0 (0) NS
(3) 0 (0) 1 (3) NS
(27) 6 (20) 2 (7) NS
(13) 4 (13) 3 (10) NS
 0.9 0.67  0.7 0.60  0.8 NS
(20) 6 (20) 7 (23) 0.03
(20) 4 (13) 6 (20) NS
(27) 8 (27) 7 (23) NS
(43) 12 (40) 15 (50) 0.01
(73) 1 (3) 9 (30) <0.0001
(17) 5 (17) 10 (33) 0.0002
/transient ischemic attack.
Table 3 Procedural Characteristics
Paroxysmal Atrial
Fibrillation
(n ¼ 60)
Persistent Atrial
Fibrillation
(n ¼ 30)
Supraventricular
Tachycardia
(n ¼ 30)
p Value
(Analysis of Variance)
Left atrial access time (min) 159  35 166  42 92  45* 0.0007
Radiofrequency duration (min) 50  19 47  20 9  10 <0.0001
Fluoroscopy time (min) 41  10 44  13 20  13 <0.0001
Activated clotting time (s) 312  31 311  20 170  32 <0.0001
Bispectral index score 42  6 38  8 43  5 NS
Systolic blood pressure 110  8 111  7 115  10 NS
pH 7.4  0.1 7.3  0.1 7.4  0.1 NS
Glucose 6.2  1.0 6.4  0.9 6.7  1.4 NS
Direct current cardioversion 0 (0) 1 (2) 0 (0) <0.0001
Values are mean  SD or n (%). *Patients with left-sided tachycardia.
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535pressure, and intraprocedural pH and glucose levels. The
periprocedural ACT was signiﬁcantly greater in patients
undergoing ablation for AF, but not between patients with
PAF and PeAF. Compared with patients with SVT who
had left-sided tachycardia, patients with PAF and PeAF had
signiﬁcantly longer left atrial access time, radiofrequency
time, and ﬂuoroscopy time. There was no signiﬁcant
difference between these parameters in patients with PAF
compared with PeAF (p ¼ 0.5, p ¼ 0.3, and p ¼ 0.2 for left
atrial access time, radiofrequency time, and ﬂuoroscopy time,
respectively). A signiﬁcantly higher proportion of patients
with PeAF underwent cardioversions during the procedure
than did patients with PAF or SVT (PeAF: 1 [2%]; PAF:
0 [0%]; SVT: 0 [0%]; p < 0.0001).
No patient developed a stroke/transient ischemic attack,
or other clinical embolic phenomenon post-procedure.
Clinical outcomes. BASELINE DEMOGRAPHICS AND PATIENT
CHARACTERISTICS. The scores for anxiety, depression, andFigure 1
Visual Analog Scale Scores for Anxiety at
Baseline, D2, and D90
There was no difference in reported anxiety levels between the patient groups. All
p ¼ NS. D ¼ day; PAF ¼ paroxysmal atrial ﬁbrillation; PeAF ¼ persistent atrial
ﬁbrillation; SVT ¼ supraventricular tachycardia.fatigue are presented in Figures 1 to 3. There were no
differences in anxiety levels between the 4 groups at the
3 time points assessed. In the assessment of depression,
patients with PeAF had an increased score at the day-2
testing time point only. Patients with PeAF rated their levels
of fatigue higher than did the other 3 study populations at
baseline and day 90. The estimated IQ as measured by the
National Adult Reading Test was not clinically different
between the 4 groups (PAF: 115  10; PeAF: 119  9;
SVT: 115  12; control: 121  7).
Neuropsychological test outcomes. IMMEDIATE (DAY 2 POST-
OPERATIVE) NEUROPSYCHOLOGICAL TEST RESULTS. Testing
was performed between 24 and 48 h after RFA in patients
with AF and SVT (mean: 36  10 h) and between 24 and
48 h after baseline testing in the AF control population
(mean: 39  18 h). POCD occurred in 17 of 60 patients
with PAF (28%; 95% conﬁdence interval [CI]: 18% to 41%),
8 of 30 patients with PeAF (27%; 95% CI: 13% to 44%), andFigure 2
Visual Analog Scale Scores for Depression at
Baseline, D2, and D90
Patients with PeAF reported higher levels of depression at day 2 only. There was no
other difference in reported levels of depression between the patient groups. *D2,
p ¼ 0.01; other, p ¼ NS. Abbreviations as in Figure 1.
Figure 3
Visual Analog Scale Scores for Fatigue at
Baseline, D2, and D90
Patients with persistent atrial ﬁbrillation reported higher levels of fatigue at
baseline and day 90. p < 0.01 Baseline and D90; D2, p ¼ NS. Abbreviations as in
Figure 1.
Figure 4 Prevalence of POCD Post-Ablation for AF
At day 90, the prevalence of POCD in patients with PAF was 13% and in patients
with PeAF was 20%. POCD ¼ post-operative cognitive dysfunction; other abbrevi-
ations as in Figure 1.
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5364 of 30 patients with SVT (13%; 95% CI: 4% to 29%). No
control patient deteriorated at this time compared with
baseline to qualify for classiﬁcation of POCD (p ¼ 0.007)
(Fig. 4).
LONG-TERM (DAY 90 POST-OPERATIVE) NEUROPSYCHOLOGICAL
TEST RESULTS. At 90 days, POCD occurred in 8 of 60
patients with PAF (13%; 95% CI: 6% to 24%), 6 of
30 patients with PeAF (20%; 95% CI: 9% to 37%), 1 of 30
patients with SVT (3%; 95% CI: 0.2% to 15%), and 0 of 30
control patients with AF (p ¼ 0.03) (Fig. 4).
There was no signiﬁcant difference in the prevalence of
POCD between the PAF and PeAF groups. When
analyzing the 3 procedural groups together, 29 of 120
patients manifested POCD at day 2 (24%; 95% CI: 16% to
32%) and 15 of 120 at day 90 post-ablation procedure (13%;
95% CI: 7% to 19%).
When comparing POCD outcomes for impairment on
individual tests (z-scores < 1.96 below controls for thatTable 4 Impaired Performance at 90 Days on Neuropsychological Te
Paroxysmal
Atrial Fibrillati
(n ¼ 60)
Consortium to Establish a Registry for Alzheimer’s Disease/
Auditory Verbal Learning Test
6 (10)
Trail Making Test Part A 4 (7)
Trail Making Test Part B 2 (3)
Digit Symbol Substitution Test 3 (5)
Controlled Oral Word Association Test 7 (12)
Consortium to Establish a Registry for Alzheimer’s Disease, Fluency 1 (2)
Grooved Pegboard Test, Dominant Hand 3 (5)
Grooved Pegboard Test, Nondominant Hand 2 (3)
Values are n (%).test), the highest frequencies were seen in the Trail Making
Test B, the CERAD Auditory Verbal Learning Test, and
the Controlled Oral Word Learning Test (Table 4).
Impairment was detected across the entire range of tests in
patients with PAF and PeAF, reﬂecting a generalized deﬁcit
in multiple tests in these patients. Abnormalities in patients
with SVT were seen in 3 of 8 tests. One patient with SVT
had evidence of neurocognitive decline at day 90, a 67-year-
old man with hypertension and diabetes who underwent
ablation of a left anterolateral pathway. During the proce-
dure, left atrial access time was 56 min, with 1.5 min of RFA
time. Of the 30 control patients with AF, an abnormality in
1 test was seen in 2 patients only (Table 4).
Factors associated with POCD. The patient data at day 2
and day 90 were analyzed by univariable analysis to identify
associations between the development of POCD and other
variables. The variables included in the univariable analysis
were age, IQ, diabetes mellitus, hypertension, intraprocedural
ACT and direct current cardioversion, and left atrial access
time. At day 2, every 1-min increase in left atrial access time
was associated with POCD on univariable analysis (odds
ratio [OR]: 1.01; 95% CI: 1.00 to 1.01; p¼ 0.04). At day 90,
increasing left atrial access time was also signiﬁcantly asso-
ciated with POCD on univariable analysis (OR: 1.01; 95%sts
on
Persistent
Atrial Fibrillation
(n ¼ 30)
Supraventricular
Tachycardia
(n ¼ 30)
Controls
(n ¼ 30) p Value
3 (10) 0 (0) 0 (0) 0.09
3 (10) 0 (0) 1 (3) 0.3
5 (17) 1 (3) 0 (0) 0.02
1 (3) 2 (7) 0 (0) 0.6
1 (3) 2 (7) 0 (0) 0.2
2 (7) 0 (0) 1 (3) 0.4
1 (3) 0 (0) 0 (0) 0.4
1 (3) 0 (0) 0 (0) 0.6
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537CI: 1.00 to 1.02; p ¼ 0.03). There were no other signiﬁcant
associations between POCD at day 90 and other variables
(age: OR 1.0, 95% CI 0.96 to 1.09; IQ: OR 1.0, 95% CI
0.96 to 1.07; diabetes: OR 0.2, 95% CI 0.03 to 0.79;
hypertension: OR 0.5, 95% CI 0.18 to 1.6; mean ACT:
OR 1.0, 95% CI 1.0 to 1.02; direct current cardioversion:
OR 1.0, 95% CI 0.71 to 1.51).
Discussion
The major ﬁnding of this study was that persistent POCD
(at day 90) occurred in 13% of patients after ablation of PAF
and 20% after ablation of PeAF. POCD was not observed in
any of the control patients with AF (no ablation procedure)
during the same time frame and in just 1 patient who
underwent SVT ablation. In this population, neither
cardiovascular risk factors nor intraprocedural direct current
cardioversion was associated with POCD. Increased left
atrial access time was signiﬁcantly associated with POCD on
univariable analysis.
Cerebral complications of ablation for AF. The combined
risk of stroke/transient ischemic attack with current proce-
dural and anticoagulation practices in ablation for AF has
been reported to be approximately 0.5% to 1.0% (1).
However, it is increasingly recognized that silent cerebral
embolic events may occur more frequently than overt stroke.
MRI studies have shown an prevalence of approximately 7%
to 14% of new, apparently asymptomatic cerebral lesions
after ablation for AF using irrigated catheters (2,3,13–16).
In the series by Gaita et al. (2), periprocedural symptomatic
stroke occurred at a frequency of 0.4%. However, post-
procedural cerebral MRI was positive for new embolic
lesions in 14% of patients who underwent irrigated RFA. In
an elegant study in canines, Haines et al. demonstrated that
microbubbles and particulate matter are responsible for new
hyperintense lesions on MRI and that these lesions correlate
with anatomic lesions on histopathologic analysis (17). In
a long-term follow-up study of 9 patients with new silent
cerebral infarction post-ablation for AF, there was an
attenuation of radiological lesions over time with no residual
lesions or scar seen on repeat MRI after a 21-month follow-
up (18). In a similar study, Deneke et al. demonstrated that
94% of asymptomatic lesions resolved at up to 1 year post-
ablation, with larger (>10 mm) acute lesions producing
chronic glial scars at long-term follow-up (19). The neuro-
logical impact of these emboli is unclear and is likely to be
determined by their size, number, and anatomic region. The
sequelae of silent cerebral infarction may include subtle
neurocognitive impairment (14), which is in turn associated
with an increased lifetime risk of cognitive impairment (20).
Etiology of POCD. The etiology of POCD is likely to be
multifactorial. The surgical procedure, anesthetic, and patient
susceptibility are all likely to inﬂuence the vulnerability to
POCD (21,22). In the current study, we compared post-
procedural cognitive function at day 2 and day 90 with
cognitive function immediately before the ablation. Weobserved an overall prevalence of POCD at day 2 of 24% and
at day 90 of 13%. The higher early prevalence may in part
reﬂect the reversible effect of anesthesia (23) on cognitive
function. In patients undergoing cardiac surgery, this effect is
most pronounced at hospital discharge and has been reported
to improve by the time of late testing after 6 weeks (20). Late
improvement may also be related to time-dependent
improvement in cognition after an initial event.
Late post-procedural cognitive impairment (day 90) is
more likely to directly reﬂect any intraprocedural cerebral
insult, including subclinical cerebral ischemia (24). In
a randomized study of 100 patients undergoing cardiac
surgery, Pugsley et al. (24) found that patients randomized
to an arterial line ﬁlter had a signiﬁcantly lower number of
cerebral microembolic events and were signiﬁcantly less
likely to have POCD at 8-week follow-up.
Neurocognitive dysfunction after coronary artery bypass
grafting may be the result of cerebral microembolism (24)
primarily originating from disruption of aortic atheroscle-
rotic lesions (25,26) as well as recirculated lipid matter from
the pericardial aspirate (27) and air entering the bypass
circuit (28). Damage to small cerebral vessels from lip-
ogenous material has been found at autopsy in patients after
bypass surgery (29). In addition, cerebral injury is believed to
be exacerbated by the systemic inﬂammatory response and
mediator release activated by cardiopulmonary bypass and
ischemia/reperfusion injury (29,30).
We observed no instances of time-dependent (over
90 days) cognitive decline in a nonprocedural AF pop-
ulation. In contrast, the AF procedural groups had a signif-
icantly higher prevalence of late POCD (day 90), and the
strongest association was with left atrial access time. Pro-
longed access to the systemic circulation with the potential
for microembolism may play an important role in the
development of POCD. In a study of post-AF ablation
MRI lesions, Gaita et al. (2) found that cardioversion and
a procedural ACT <250 s were the only factors associated
with the development of new lesions on imaging. Interest-
ingly, in an analysis of patients with PeAF undergoing
cardioversion alone, no silent embolic lesions were detected
(2). This raises the suggestion that the prothrombotic milieu
induced by catheter ablation is an important factor in the
thromboembolic risk associated with cardioversion during an
AF ablation procedure. In our population with a uniformly
targeted ACT of 300 to 350 s, there was no association
between either ACT or the prevalence of cardioversion and
the risk of POCD.
Interestingly, in our relatively low-risk population, we
found that POCD occurs independently of conventional
cardiovascular risk factors. Increasing age and poorer
performance on the estimated intelligence test were not
associated with an increased prevalence of POCD in this
study. This may be due to the relative homogeneity of the
study population with uniformly young age (mean: 56  10
years), low prevalence of cardiovascular risk factors, and high
estimated IQ scores assessed by the National Adult Reading
Medi et al. JACC Vol. 62, No. 6, 2013
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538Test (mean: 115  14). Different results may have been
obtained if a broader spectrum of patients (older with higher
CHADS2 scores) had been studied. The reasons for this
remain speculative, but other factors not routinely screened
may play a role. Cerebral hemodynamics, platelet function
(31), and systemic inﬂammation (32) have been shown to be
abnormal in patients with AF, and variability in these
parameters may affect cognitive reserve and susceptibility to
POCD.
Intraprocedural hypotension may directly cause cerebral
injury or may exacerbate cerebral injury due to micro-
embolism (33). However, hemodynamic effects are unlikely
to have played a major role in POCD in our population,
because the majority of patients had normal left ventricular
function and were normotensive throughout the procedure.
We observed only 1 patient in the SVTgroupwith evidence
of late cognitive dysfunction, a 67-year-old man who under-
went trans-septal puncture for a left anterolateral pathway
ablation. A combination of procedural (left atrial access) and
patient-related factors (age, diabetes, and hypertension) may
have contributed to the development of cognitive dysfunction
post-procedure in this individual. This patient had abnormal
results on only 2 of the 8 tests.
Prior studies of cognitive dysfunction after cardiac
procedures. POCD has been most extensively studied in
patients after coronary artery bypass grafting. POCD has
been documented in approximately 53% of patients at
hospital discharge, 36% at 6 weeks post-operatively, and 24%
at 6 months post-operatively (20). Although there is atten-
uation in the prevalence of POCD in the short-intermediate
period after cardiac surgery, POCD at hospital discharge was
signiﬁcantly associated with both the severity and prevalence
of cognitive decline at 5 years (20).
In a prior small series, Schwarz et al. compared the results
of neurocognitive testing of 23 patients with AF undergoing
ablation with either RFA or cryoablation with those of
healthy community-based volunteers (14). By comparison,
the patients with AF as a group had reduced scores on verbal
memory post-ablation. Overall, 56.5% of patients who
underwent ablation deteriorated from baseline on the verbal
memory tests, which comprised 1 of 5 cognitive domains
tested, compared with 17% of controls.
Clinical implications. This study demonstrates that abla-
tion for AF may be associated with subtle neurocognitive
impairment that persists at 90 days after the procedure.
Further studies are required to determine whether these
subtle abnormalities will be associated with an increased
lifetime risk of cognitive impairment. Alternatively, cure of
AF may in itself be protective in the longer term. The long-
term cognitive implications will be an important determi-
nant of procedural safety. Furthermore, strategies that
reduce the left atrial access time, optimize the anti-
coagulation approach, and address the timing of direct
current reversion may have an effect on the prevalence of
POCD.Study limitations. Many departments have recently adop-
ted an approach of performing ablation for AF without
interruption of warfarin therapy. Although this may poten-
tially reduce the prevalence of POCD, a recent study showed
an prevalence of clinical embolism of 0.6% (similar to that
reported in earlier studies) despite a therapeutic international
normalized ratio and ACT >300 s (34).
We did not perform diffusion-weighted MRI pre-
ablation and post-ablation; therefore, correlation of neuro-
cognitive outcomes with silent cerebral emboli could not be
performed.
All procedures were performed under general anesthesia,
and these results may not necessarily be applicable to
patients who undergo the procedure under conscious seda-
tion. Nevertheless, POCD persisted well beyond the time
when the effects of anesthesia may continue to affect
cognitive function.
Conclusions
Ablation for AF is associated with a 13% to 20% prevalence of
POCD in patients with AF at long-term follow-up. These
results were seen in a patient population with predominant
CHADS2 scores of 0 to 1, representing the majority of
patients undergoing ablation for AF. The long-term impli-
cations of these subtle changes require further study.
Reprint requests and correspondence: Prof. Jonathan M. Kalman,
Department of Cardiology, The Royal Melbourne Hospital, Royal
Parade, Parkville, Victoria 3050, Australia. E-mail: jon.kalman@
mh.org.au.REFERENCES
1. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on
the methods, efﬁcacy, and safety of catheter ablation for human atrial
ﬁbrillation. Circ Arrhythm Electrophysiol 2010;3:32–8.
2. Gaita F, CaponiD, PianelliM, et al. Radiofrequency catheter ablation of
atrial ﬁbrillation: a cause of silent thromboembolism? Magnetic reso-
nance imaging assessment of cerebral thromboembolism in patients
undergoing ablation of atrial ﬁbrillation. Circulation 2010;122:1667–73.
3. Schrickel JW, Lickfett L, Lewalter T, et al. Incidence and predictors of
silent cerebral embolism during pulmonary vein catheter ablation for
atrial ﬁbrillation. Europace 2010;12:52–7.
4. Medi C, Sparks PB, Morton JB, et al. Pulmonary vein antral isolation
for paroxysmal atrial ﬁbrillation: results from long-term follow-up.
J Cardiovasc Electrophysiol 2011;22:137–41.
5. Rosso R, Sparks PB, Morton JB, et al. Vagal paroxysmal atrial ﬁbril-
lation: prevalence and ablation outcome in patients without structural
heart disease. J Cardiovasc Electrophysiol 2010;21:489–93.
6. Canadian study of health and aging: study methods and prevalence of
dementia. CMAJ 1994;150:899–913.
7. Evered LA, Silbert BS, Scott DA, et al. Plasma amyloid beta 42 and
amyloid beta 40 levels are associated with early cognitive dysfunction.
Ann Thorac Surg 2009;88:1426–32.
8. Silbert BS, Scott DA, Evered LA, et al. A comparison of the effect of
high- and low-dose fentanyl on the incidence of postoperative cognitive
dysfunction after coronary artery bypass surgery in the elderly. Anes-
thesiology 2006;104:1137–45.
9. Evered LA, Silbert BS, Scott DA. Postoperative cognitive dysfunction
and aortic atheroma. Ann Thorac Surg 2010;89:1091–7.
JACC Vol. 62, No. 6, 2013 Medi et al.
August 6, 2013:531–9 Cognitive Dysfunction Post-Ablation for AF
53910. Evered LA, Silbert BS, Scott DA, Maruff P, Ames D, Choong PF.
Preexisting cognitive impairment and mild cognitive impairment in
subjects presenting for total hip joint replacement. Anesthesiology
2011;114:1297–304.
11. Rasmussen LS, Larsen K, Houx P, Skovgaard LT, Hanning CD,
Moller JT. The assessment of postoperative cognitive function. Acta
Anaesthesiol Scand 2001;45:275–89.
12. Ludbrook G. Multiple comparison procedures updated. Clin Exp
Pharmacol Physiol 1998;25:1032–7.
13. Neumann T, Kuniss M, Conradi G, et al. MEDAFI-Trial (Micro-
embolization during ablation of atrial ﬁbrillation): comparison of
pulmonary vein isolation using cryoballoon technique vs. radio-
frequency energy. Europace 2001;13:37–44.
14. Schwarz N, Kuniss M, Nedelmann M, et al. Neuropsychological
decline after catheter ablation of atrial ﬁbrillation. Heart Rhythm 2010;
7:1761–7.
15. Herrera-Siklody C, Deneke T, Hocini M, et al. Incidence of asymp-
tomatic intracranial embolic events after pulmonary vein isolation:
comparison of different atrial ﬁbrillation technologies in a multicentre
study. J Am Coll Cardiol 2011;58:681–8.
16. Gaita F, Leclercq JF, Schumacher B, et al. Incidence of silent cerebral
thromboembolic lesions after atrial ﬁbrillation ablation may change
according to technology used: comparison of irrigated radiofrequency,
multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Elec-
trophysiol 2011;22:961–8.
17. Haines DE, Stewart MT, Barka ND, et al. Microembolism and
catheter ablation II: effects of cerebral microemboli injection in a canine
model. Circ Arrhythm Electrophysiol 2013;6:23–30.
18. Rillig A, Meyerfeldt U, Tilz RR, et al. Incidence and long-term follow-
up of silent cerebral lesions after pulmonary vein isolation using
a remote robotic navigation system as compared with manual ablation.
Circ Arrhythm Electrophysiol 2012;5:15–21.
19. Deneke T, Shin DI, Balta O, et al. Postablation asymptomatic cerebral
lesions: long-term follow-up using magnetic resonance imaging. Heart
Rhythm 2011;8:1705–11.
20. Newman MF, Kirchner JL, Phillips-Bute B, et al. Longitudinal
assessment of neurocognitive function after coronary-artery bypass
surgery. N Engl J Med 2001;344:395–402.
21. Evered LA, Scott DA, Silbert BS, Maruff P. Postoperative cognitive
dysfunction is independent of type of surgery and anesthetic. Anesth
Analg 2001;112:1179–85.22. Monk TG, Weldon BC, Garvan CW, et al. Predictors of cognitive
dysfunction after noncardiac surgery. Anesthesiology 2008;108:18–30.
23. Terrando N, Eriksson LI, Kyu Ryu J, et al. Resolving postoperative
neuroinﬂammation and cognitive decline. Ann Neurol 2011;70:
986–95.
24. Pugsley W, Klinger L, Paschalis C, Treasure T, Harrison M,
Newman S. The impact of microemboli during cardiopulmonary
bypass on neuropsychological functioning. Stroke 1994;25:1393–9.
25. Mackensen GB, Ti LK, Phillips-Bute BG, Mathew JP, Newman MF,
Grocott HP. Cerebral embolization during cardiac surgery: impact of
aortic atheroma burden. Br J Anaesth 2003;91:656–61.
26. Blauth CI, Cosgrove DM, Webb BW, et al. Atheroembolism from the
ascending aorta. An emerging problem in cardiac surgery. J Thorac
Cardiovasc Surg 1992;103:1104–11.
27. Brooker RF, Brown WR, Moody DM, et al. Cardiotomy suction:
a major source of brain lipid emboli during cardiopulmonary bypass.
Ann Thorac Surg 1998;65:1651–5.
28. Hogue CW Jr., Palin CA, Arrowsmith JE. Cardiopulmonary bypass
management and neurologic outcomes: an evidence-based appraisal of
current practices. Anesth Analg 2006;103:21–37.
29. Selnes OA, McKhann GM. Neurocognitive complications after coro-
nary artery bypass surgery. Ann Neurol 2005;57:615–21.
30. Gao L, Taha R, Gauvin D, Othmen LB, Wang Y, Blaise G. Post-
operative cognitive dysfunction after cardiac surgery. Chest 2005;128:
3664–70.
31. Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-
selectin on platelets is a risk factor for silent cerebral infarction in patients
with atrial ﬁbrillation: role of nitric oxide. Circulation 1998;98:1721–7.
32. Gersh BJ, Tsang TS, Seward JB. The changing epidemiology and
natural history of nonvalvular atrial ﬁbrillation: clinical implications.
Trans Am Clin Climatol Assoc 2004;115:149–59.
33. Hogue CW, Gottesman RF, Stearns J. Mechanisms of cerebral injury
from cardiac surgery. Crit Care Clin 2008;24:83–98, viii–ix.
34. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and
management of major bleeding complications in patients undergoing
catheter ablation of atrial ﬁbrillation: the impact of periprocedural
therapeutic international normalized ratio. Circulation 2010;121:
2550–6.
Key Words: ablation - atrial ﬁbrillation - neurocognitive dysfunction -
outcomes.
